Indivior Shares Soar 1.56% on Earnings Beat, FDA Approval

Indivior (INDV) shares surged 1.56% today, marking the sixth consecutive day of gains, with a cumulative increase of 33.37% over the past six days. The stock price reached its highest level since February 2025, with an intraday gain of 1.73%.

Indivior's recent stock price movements can be attributed to several key developments. The company reported a significant earnings beat for the first quarter of 2025, with revenue reaching US$266 million, 11% above analyst expectations, and earnings per share (EPS) at US$0.38, 77% higher than forecasts. This strong financial performance has bolstered investor confidence in the company's growth prospects.

Additionally, Indivior's flagship product, Sublocade, received expanded FDA approval. This regulatory milestone is expected to enhance the product's market share, despite the competitive landscape. The expanded approval allows for broader use of Sublocade, potentially driving increased sales and revenue for the company.

Furthermore, Indivior reaffirmed its earnings guidance for the fiscal year 2025, maintaining a stable outlook under U.S. GAAP. This reaffirmation indicates the company's confidence in its financial performance and future growth prospects, providing reassurance to investors and contributing to the positive sentiment surrounding the stock.